Lorazepam Effects on Neuroimaging Measures

Phase < 1

Waitlist Available

Led By Juan A Gallego, MD

Research Sponsored by Northwell Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks

Summary

This trial studies how lorazepam, a common anxiety and sleep medication, affects brain connectivity in people undergoing brain scans. The researchers believe lorazepam will improve communication between different brain regions.

Eligible Conditions

Ativan
Neuroimaging

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

To understand the impact of lorazepam on functional connectivity measures collected using resting state functional magnetic imaging (rs-fMRI).

Secondary study objectives

The goal is to study the impact of lorazepam on glutamate, glutamine and GABA in the striatum.

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Lorazepam firstExperimental Treatment2 Interventions

This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.

Group II: Placebo firstPlacebo Group2 Interventions

This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Do I qualify?Apply below to find out